Revista Portuguesa De Cardiologia最新文献

英文中文

Cardiopulmonary Exercise Testing in Portugal: Bridging the Gap Between Evidence and Clinical Practice. 心肺运动测试在葡萄牙：弥合证据和临床实践之间的差距。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-01-22 DOI: 10.1016/j.repc.2026.01.004

P Rio

引用次数: 0

Extravascular ICDs in Portugal: From concept to clinical reality. 葡萄牙的血管外icd：从概念到临床现实。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-01-15 DOI: 10.1016/j.repc.2026.01.002

Serge Boveda

引用次数: 0

Integrating Natriuretic Peptide Screening in Diabetic Patients: Practical Insights from a Neurosurgical Perspective. 整合糖尿病患者的利钠肽筛选：从神经外科角度的实际见解。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-01-09 DOI: 10.1016/j.repc.2025.11.006

Shang Gechu, Wang Guan

引用次数: 0

Right hemothorax due to a ruptured descending thoracic aortic aneurysm. 右胸血是由胸降主动脉瘤破裂引起的。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-01-09 DOI: 10.1016/j.repc.2025.09.011

Hisato Takagi

引用次数: 0

Late thrombosis of a left atrial appendage occlusion in a patient with cancer. 癌症患者左心耳闭塞的晚期血栓形成。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-01-09 DOI: 10.1016/j.repc.2025.09.012

María Noelia Pizá, Lucía Fernández Gassó, Teresa López-Fernández

引用次数: 0

Efficacy and safety of off-pump versus on-pump coronary artery bypass grafting in chronic obstructive pulmonary disease patients: A systematic review and meta-analysis 非体外循环与非体外循环冠状动脉旁路移植术治疗慢性阻塞性肺疾病的疗效和安全性：一项系统综述和荟萃分析

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-01-01 DOI: 10.1016/j.repc.2025.06.008

Danish Hassan , Kashish Zehra Manjee , Tungki Pratama Umar , Mohammad Al Diab Al Azzawi , Salem Elshenawy , Wajeeh Ahmed Khan , Syed Rayyan Ahmed , Muhammad Sohaib Khan , Marium Amjad , Yasmine Adel Mohammed

Introduction and objectives

Patients with chronic obstructive pulmonary disease (COPD) undergoing coronary artery bypass grafting (CABG) face significant perioperative risks. The choice between off-pump and on-pump CABG techniques can impact clinical outcomes, particularly related to pulmonary function and postoperative recovery. This meta-analysis aims to evaluate the clinical efficacy and safety of off-pump versus on-pump CABG in patients with COPD.

Methods

A comprehensive search of medical databases including PubMed and Google Scholar was conducted to identify relevant studies comparing off-pump and on-pump CABG in COPD patients. The main outcomes included postoperative respiratory complications, mortality rates, length of hospital stay, and overall recovery. Results were pooled as relative risks (RR) or mean differences (MD) with 95% confidence intervals (CI).

Results

A total of seven studies (two randomized controlled trials (RCTs), one sub-study from a previous RCT, and four observational studies) comprising 1071 patients were included in the analysis. While postoperative respiratory complications were lower in the off-pump group, the difference was not statistically significant. However, off-pump CABG was significantly associated with reduced mortality (RR 0.21; 95% CI: [0.08, 0.54], p=0.001), shorter hospital stays (MD=−2.34; 95% CI: [−4.51, −0.17], p=0.03), reduced need for mechanical ventilatory support (MD=−4.73; 95% CI: [−6.17, −3.29], p<0.00001), and lower incidence of low cardiac output (RR=0.43, 95% CI [0.19, 0.99], p=0.05).

Conclusion

Off-pump CABG provides significant benefits over on-pump CABG in COPD patients by reducing mortality, hospital stay duration, the need for mechanical ventilatory support, and low cardiac output. The observed reduction in postoperative respiratory complications, although not statistically significant, may indicate potential clinical benefits of off-pump CABG. Further large-scale RCTs are needed to confirm these findings.

简介和目的：慢性阻塞性肺疾病（COPD）患者行冠状动脉旁路移植术（CABG）面临显著的围手术期风险。停泵和开泵CABG技术的选择会影响临床结果，特别是与肺功能和术后恢复有关。本荟萃分析旨在评估非泵送与泵送CABG治疗COPD患者的临床疗效和安全性。方法：对PubMed和谷歌Scholar等医学数据库进行全面检索，以确定比较非泵送和泵送CABG在COPD患者中的相关研究。主要结局包括术后呼吸系统并发症、死亡率、住院时间和总体恢复。结果汇总为相对危险度（RR）或平均差异（MD）， 95%置信区间（CI）。结果：共纳入7项研究（2项随机对照试验（RCT）、1项既往RCT的子研究和4项观察性研究），共1071例患者。停泵组术后呼吸并发症较低，但差异无统计学意义。然而，非泵送CABG与降低死亡率（RR 0.21; 95% CI: [0.08 - 0.54]， P=0.001）、缩短住院时间（MD=-2.34; 95% CI: [-4.51, -0.17]， P=0.03）、减少机械通气支持需求（MD=-4.73; 95% CI:[-6.17, -3.29]）显著相关。结论：非泵送CABG通过降低死亡率、住院时间、机械通气支持需求和低心输出量，为COPD患者提供了显著的益处。观察到的术后呼吸并发症的减少，虽然没有统计学意义，但可能表明非体外循环冠状动脉搭桥的潜在临床益处。需要进一步的大规模随机对照试验来证实这些发现。

{"title":"Efficacy and safety of off-pump versus on-pump coronary artery bypass grafting in chronic obstructive pulmonary disease patients: A systematic review and meta-analysis","authors":"Danish Hassan , Kashish Zehra Manjee , Tungki Pratama Umar , Mohammad Al Diab Al Azzawi , Salem Elshenawy , Wajeeh Ahmed Khan , Syed Rayyan Ahmed , Muhammad Sohaib Khan , Marium Amjad , Yasmine Adel Mohammed","doi":"10.1016/j.repc.2025.06.008","DOIUrl":"10.1016/j.repc.2025.06.008","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Patients with chronic obstructive pulmonary disease (COPD) undergoing coronary artery bypass grafting (CABG) face significant perioperative risks. The choice between off-pump and on-pump CABG techniques can impact clinical outcomes, particularly related to pulmonary function and postoperative recovery. This meta-analysis aims to evaluate the clinical efficacy and safety of off-pump versus on-pump CABG in patients with COPD.</div></div><div><h3>Methods</h3><div>A comprehensive search of medical databases including PubMed and Google Scholar was conducted to identify relevant studies comparing off-pump and on-pump CABG in COPD patients. The main outcomes included postoperative respiratory complications, mortality rates, length of hospital stay, and overall recovery. Results were pooled as relative risks (RR) or mean differences (MD) with 95% confidence intervals (CI).</div></div><div><h3>Results</h3><div>A total of seven studies (two randomized controlled trials (RCTs), one sub-study from a previous RCT, and four observational studies) comprising 1071 patients were included in the analysis. While postoperative respiratory complications were lower in the off-pump group, the difference was not statistically significant. However, off-pump CABG was significantly associated with reduced mortality (RR 0.21; 95% CI: [0.08, 0.54], p=0.001), shorter hospital stays (MD=−2.34; 95% CI: [−4.51, −0.17], p=0.03), reduced need for mechanical ventilatory support (MD=−4.73; 95% CI: [−6.17, −3.29], p<0.00001), and lower incidence of low cardiac output (RR=0.43, 95% CI [0.19, 0.99], p=0.05).</div></div><div><h3>Conclusion</h3><div>Off-pump CABG provides significant benefits over on-pump CABG in COPD patients by reducing mortality, hospital stay duration, the need for mechanical ventilatory support, and low cardiac output. The observed reduction in postoperative respiratory complications, although not statistically significant, may indicate potential clinical benefits of off-pump CABG. Further large-scale RCTs are needed to confirm these findings.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 1","pages":"Pages 25-36"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Portuguese National Registry on cardiac implantable electronic devices (2021–2022) 葡萄牙国家心脏植入式电子设备登记处（2021-2022）。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-01-01 DOI: 10.1016/j.repc.2025.08.008

Pedro Santarém Semedo , Paulo Fonseca , Sílvia Ribeiro , Alexandra Castro , Pedro Marques , Daniel Bonhorst , Víctor Sanfins

Introduction and objectives

We present data from the national registry of implantable cardiac devices (CIED) promoted by the Portuguese Association of Pacing and Electrophysiology for the years 2021 and 2022.

Methods

This is an annual, voluntary, multicenter registry with retrospective data collection. The evolution of interventions over time and the distribution by type of device are evaluated.

Results

The overall trend has been one of growth in previous years and during the biennium, with an increase in the total number of interventions across all CIED types. The only exception was cardiac resynchronization therapy associated with defibrillation capacity, which saw a decrease from 2021 to 2022.

Conclusions

Following a period of stagnation in the years leading up to this report, possibly due to COVID-19, there was a significant increase in procedures in the years under review. This growth highlights the vitality of the sector in Portugal and its strong position within Europe. This registry allows for the monitoring of the situation of Portuguese centers in relation to CIED procedures and their evolution.

简介和目的：我们提供了由葡萄牙起搏和电生理协会推广的2021年和2022年植入式心脏装置（CIED）国家登记处的数据。方法：这是一项年度、自愿、多中心的回顾性数据收集登记。评估了干预措施随时间的演变和设备类型的分布。结果：前几年和本两年期的总体趋势是增长，所有CIED类型的干预措施总数都有所增加。唯一的例外是与除颤能力相关的心脏再同步化治疗，从2021年到2022年有所下降。结论：在本报告发布之前的几年中，可能是由于COVID-19的原因，经历了一段停滞期，在本报告审查的几年中，程序显著增加。这一增长凸显了葡萄牙旅游业的活力及其在欧洲的强大地位。该登记处可以监测葡萄牙中心在CIED程序及其演变方面的情况。

{"title":"Portuguese National Registry on cardiac implantable electronic devices (2021–2022)","authors":"Pedro Santarém Semedo , Paulo Fonseca , Sílvia Ribeiro , Alexandra Castro , Pedro Marques , Daniel Bonhorst , Víctor Sanfins","doi":"10.1016/j.repc.2025.08.008","DOIUrl":"10.1016/j.repc.2025.08.008","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>We present data from the national registry of implantable cardiac devices (CIED) promoted by the Portuguese Association of Pacing and Electrophysiology for the years 2021 and 2022.</div></div><div><h3>Methods</h3><div>This is an annual, voluntary, multicenter registry with retrospective data collection. The evolution of interventions over time and the distribution by type of device are evaluated.</div></div><div><h3>Results</h3><div>The overall trend has been one of growth in previous years and during the biennium, with an increase in the total number of interventions across all CIED types. The only exception was cardiac resynchronization therapy associated with defibrillation capacity, which saw a decrease from 2021 to 2022.</div></div><div><h3>Conclusions</h3><div>Following a period of stagnation in the years leading up to this report, possibly due to COVID-19, there was a significant increase in procedures in the years under review. This growth highlights the vitality of the sector in Portugal and its strong position within Europe. This registry allows for the monitoring of the situation of Portuguese centers in relation to CIED procedures and their evolution.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 1","pages":"Pages 1-8"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world dapagliflozin treatment patterns in Portuguese patients with heart failure with reduced ejection fraction 现实世界中，达格列净治疗葡萄牙心力衰竭伴射血分数降低患者的模式。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-01-01 DOI: 10.1016/j.repc.2025.08.007

Aurora Andrade , Sara Gonçalves , Ana Batista , Ana Teresa Timóteo , Ana Oliveira Soares , Fátima Franco , Otília Simões , Marisa Pardal , Mário Almeida , Margarida Lopes , Filipa Bernardo , José Silva-Cardoso

Introduction and objectives

Heart failure with reduced ejection fraction (HFrEF) poses a significant challenge to healthcare. While clinical trials have shown the therapeutic benefits of dapagliflozin in patients with HFrEF, it is essential to understand treatment patterns and patient characteristics in real-world settings. The EVOLUTION-HF study sought to address this gap by analyzing real-world data.

Methods

EVOLUTION-HF is a retrospective cohort study conducted at eight sites in Portugal, which included patients who began treatment with dapagliflozin for HFrEF. Medical records were reviewed to collect information on the initiation date of dapagliflozin (the index date) and at the six- and 12-month follow-ups.

Results

This study included 228 patients. The majority were male, with an average age of 65 years, a mean left ventricular ejection fraction of 29%, and 85% classified as NYHA class II. More prevalent comorbidities were dyslipidemia (59%) and arterial hypertension (56%). On the index date, baseline medications showed a high utilization of standard HFrEF therapies: 92% of patients received betablockers, 71% were on aldosterone antagonists, and 55% were taking angiotensin receptor-neprilysin inhibitors. At the end of the follow-up period, there was a significant increase in the dosage of beta-blockers and a decrease in the dosage of loop diuretics. A low discontinuation rate of 5% was observed for dapagliflozin.

Conclusions

These findings support the established safety profile of dapagliflozin. The patient characteristics in the EVOLUTION-HF study closely resemble those in the DAPA-HF randomized trial. The observed treatment patterns indicate an optimization in guideline-directed medical therapy.

前言和目的：心力衰竭伴射血分数降低（HFrEF）对医疗保健提出了重大挑战。虽然临床试验显示了达格列净对HFrEF患者的治疗益处，但在现实环境中了解治疗模式和患者特征是至关重要的。EVOLUTION-HF研究试图通过分析真实世界的数据来解决这一差距。方法：EVOLUTION-HF是一项在葡萄牙8个地点进行的回顾性队列研究，其中包括开始使用达格列净治疗HFrEF的患者。审查了医疗记录，以收集有关开始使用达格列净的日期（索引日期）以及6个月和12个月随访的信息。结果：本研究纳入228例患者。大多数患者为男性，平均年龄65岁，平均左室射血分数为29%，其中85%为NYHA II级。更普遍的合并症是血脂异常（59%）和动脉高血压（56%）。在索引日期，基线药物显示标准HFrEF疗法的使用率很高：92%的患者接受了β受体阻滞剂，71%的患者接受了醛固酮拮抗剂，55%的患者接受了血管紧张素受体-肾上腺素抑制剂。在随访期结束时，受体阻滞剂的剂量显著增加，袢利尿剂的剂量显著减少。达格列净的停药率很低，为5%。结论：这些发现支持已建立的达格列净的安全性。EVOLUTION-HF研究中的患者特征与DAPA-HF随机试验中的患者特征非常相似。观察到的治疗模式表明，在指导药物治疗优化。

{"title":"Real-world dapagliflozin treatment patterns in Portuguese patients with heart failure with reduced ejection fraction","authors":"Aurora Andrade , Sara Gonçalves , Ana Batista , Ana Teresa Timóteo , Ana Oliveira Soares , Fátima Franco , Otília Simões , Marisa Pardal , Mário Almeida , Margarida Lopes , Filipa Bernardo , José Silva-Cardoso","doi":"10.1016/j.repc.2025.08.007","DOIUrl":"10.1016/j.repc.2025.08.007","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Heart failure with reduced ejection fraction (HFrEF) poses a significant challenge to healthcare. While clinical trials have shown the therapeutic benefits of dapagliflozin in patients with HFrEF, it is essential to understand treatment patterns and patient characteristics in real-world settings. The EVOLUTION-HF study sought to address this gap by analyzing real-world data.</div></div><div><h3>Methods</h3><div>EVOLUTION-HF is a retrospective cohort study conducted at eight sites in Portugal, which included patients who began treatment with dapagliflozin for HFrEF. Medical records were reviewed to collect information on the initiation date of dapagliflozin (the index date) and at the six- and 12-month follow-ups.</div></div><div><h3>Results</h3><div>This study included 228 patients. The majority were male, with an average age of 65 years, a mean left ventricular ejection fraction of 29%, and 85% classified as NYHA class II. More prevalent comorbidities were dyslipidemia (59%) and arterial hypertension (56%). On the index date, baseline medications showed a high utilization of standard HFrEF therapies: 92% of patients received betablockers, 71% were on aldosterone antagonists, and 55% were taking angiotensin receptor-neprilysin inhibitors. At the end of the follow-up period, there was a significant increase in the dosage of beta-blockers and a decrease in the dosage of loop diuretics. A low discontinuation rate of 5% was observed for dapagliflozin.</div></div><div><h3>Conclusions</h3><div>These findings support the established safety profile of dapagliflozin. The patient characteristics in the EVOLUTION-HF study closely resemble those in the DAPA-HF randomized trial. The observed treatment patterns indicate an optimization in guideline-directed medical therapy.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 1","pages":"Pages 13-21"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The APAPE National Registry of Cardiac Implantable Devices – A Tool of Vitality and Progress for Portuguese Cardiology APAPE国家心脏植入装置注册-葡萄牙心脏病学的活力和进步工具

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-01-01 DOI: 10.1016/j.repc.2025.12.004

Vítor Paulo Martins

引用次数: 0

Left ventricular cardiomyopathy due to CPT II hereditary deficiency. Keys to an infrequent diagnosis CPT II遗传性缺乏所致的左室性心肌病。罕见诊断的关键。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia

Pub Date : 2026-01-01 DOI: 10.1016/j.repc.2025.08.006

Lorena Herrador , Elena García Arumi , Fernando de Frutos

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Revista Portuguesa De Cardiologia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀